IDSA/SHEA 2021 Focused Update on Clostridioides difficile Infection Management

This guideline prioritizes fidaxomicin over vancomycin and updates on adjunct therapies.

IDSASHEAClostridioides difficileinfection managementfidaxomicin Clostridioides difficile Infection

Authors: Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH

Citation: Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021;73(5):e1029-e1044. doi:10.1093/cid/ciab549

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

Practice-changing Impact 5/5

The guideline introduces a major shift in CDI treatment by prioritizing fidaxomicin over vancomycin, significantly impacting clinical practice.

Evidence Grade: High

The high-quality evidence from MODIFY I/II trials supports the shift to fidaxomicin, demonstrating clear improved outcomes.

What's New / Changed vs. Prior Version

Fidaxomicin is now the preferred agent over vancomycin for initial CDI due to its superior sustained cure rates. Bezlotoxumab is recommended as an adjunct for high-risk patients. Metronidazole is no longer recommended for initial CDI treatment.

Key Recommendations

Fidaxomicin (200 mg twice daily for 10 days) is preferred over vancomycin for initial CDI treatment (Strong recommendation, High-quality evidence). Bezlotoxumab should be used as an adjunct in high-risk patients, including those aged ≥65, immunocompromised, or with severe CDI (Strong recommendation, moderate evidence). Fidaxomicin is also preferred for recurrent CDI (Strong recommendation, High-quality evidence). Fecal microbiota transplantation (FMT) is recommended for multiply recurrent CDI (Conditional recommendation, moderate evidence).

Practice Impact for Pharmacists

Pharmacists should prioritize fidaxomicin in order sets for initial and recurrent CDI cases.
Review and update treatment protocols to reflect metronidazole's removal as an option for initial CDI.
Consider eligibility criteria for bezlotoxumab adjunctive therapy in high-risk patients.

Implementation Considerations

Cost of fidaxomicin may limit access; budget planning and insurance coverage assessment are required. Healthcare providers need training on new treatment protocols, and electronic health record (EHR) updates will be necessary to reflect guideline changes.

Controversies / Dissenting Opinions

None noted

Editor's Note

The guideline focuses primarily on key pharmacological updates; full text was not accessed, limiting depth on implementation nuances.

Full text source: Manual Upload

More in Clostridioides difficile Infection

Read the full text at the journal →